Nontuberculous Mycobacterial Pulmonary Disease in the Immunocompromised Host.
HIV
Immunocompromised host
Immunosuppressive agents
Mycobacterium infections
Nontuberculous
Nontuberculous mycobacteria
Organ transplantation
Transplant recipients
Journal
Clinics in chest medicine
ISSN: 1557-8216
Titre abrégé: Clin Chest Med
Pays: United States
ID NLM: 7907612
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
27
10
2023
Statut:
ppublish
Résumé
The immunocompromised host is at an increased risk for pulmonary and extrapulmonary NTM infections. Where data are available in these specific populations, increased mortality is observed with NTM disease. Prior to starting therapy for NTM disease, providers should ensure diagnostic criteria are met as treatment is long and often associated with significant side effects and toxicities. Treatment should involve 2 to 4 agents and be guided by cultures and antimicrobial susceptibilities. Drug interactions are important to consider, especially in those with HIV or transplant recipients. Whenever possible, immunosuppression should be reduced or changed.
Identifiants
pubmed: 37890919
pii: S0272-5231(23)00048-5
doi: 10.1016/j.ccm.2023.06.007
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
829-838Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.